Daniel Lin, MD
Dr. Lin is Professor and Chief of Urologic Oncology in the Department of Urology, the Director of the Institute for Prostate Cancer Research, and holds the Pritt Family endowed Chair in Prostate Cancer Research at the University of Washington School of Medicine. Dr. Lin received his undergraduate degree from Stanford University and his medical degree from Vanderbilt University. He completed his urology residency at the University of Washington and urologic oncology fellowship at Memorial Sloan-Kettering Cancer Center, followed by an American Foundation for Urologic Disease (AFUD) Physician Scholar Award at the Fred Hutchinson Cancer Research Center. Dr. Lin’s major basic/translational research interests are in prostate chemoprevention and molecular/genomic biomarkers for aggressive prostate cancer, and his major clinical research efforts are in prostate cancer active surveillance and novel strategies in high-risk prostate cancer. Dr. Lin serves on various national committees including the guideline panels for the National Comprehensive Cancer Network (NCCN) and the American Urological Association (AUA). Dr. Lin receives funding from multiple peer-reviewed grants from the National Cancer Institute (NCI) and Department of Defense (DOD).
Financial relationships
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:DendreonDate added:Date updated:04/02/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Clovis OncologyDate added:Date updated:04/02/2023
-
Attribution:SelfType of financial relationship:OtherIneligible company:MagForce USADate added:Date updated:04/02/2023
-
Attribution:SelfType of financial relationship:OtherIneligible company:Genomic Health, Inc.Date added:Date updated:04/02/2023
-
Attribution:SelfType of financial relationship:OtherIneligible company:NIH/NCIDate added:Date updated:04/02/2023
-
Attribution:SelfType of financial relationship:OtherIneligible company:Department of DefenseDate added:Date updated:04/02/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:DendreonDate added:Date updated:04/02/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Clovis OncologyDate added:Date updated:04/02/2023
-
Attribution:SelfType of financial relationship:OtherIneligible company:MagForce USADate added:Date updated:04/02/2023
-
Attribution:SelfType of financial relationship:OtherIneligible company:Genomic Health, Inc.Date added:Date updated:04/02/2023